Steward Partners Investment Advisory LLC Buys 6,701 Shares of Sanofi (NASDAQ:SNY)

Steward Partners Investment Advisory LLC lifted its position in shares of Sanofi (NASDAQ:SNY) by 12.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,973 shares of the company’s stock after acquiring an additional 6,701 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Sanofi were worth $2,893,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNY. Synergy Asset Management LLC acquired a new position in Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. lifted its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the period. Sierra Ocean LLC acquired a new position in shares of Sanofi in the fourth quarter worth approximately $44,000. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi in the fourth quarter worth approximately $54,000. Institutional investors own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Price Performance

Shares of SNY opened at $59.25 on Friday. Sanofi has a 52-week low of $45.22 and a 52-week high of $59.72. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The business’s 50 day moving average price is $52.44 and its two-hundred day moving average price is $52.73. The firm has a market cap of $150.37 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.